Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fc-CLEC-2
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Fc-CLEC-2 (also known as CLEC-2-Fc or CLEC2.Fc) is a recombinant fusion protein consisting of the extracellular domain of C-type lectin-like receptor 2 (CLEC-2, encoded by the CLEC1B gene) fused to an immunoglobulin Fc domain (typically human IgG1 Fc). It acts as a soluble decoy receptor or agonist depending on the context. Fc-CLEC-2 physically binds to podoplanin (PDPN), the endogenous ligand of CLEC-2, which is expressed on various cell types including kidney podocytes, lymphatic endothelial cells, and inflammatory macrophages. In research settings, Fc-CLEC-2 is used to study podoplanin-CLEC-2 interactions, podocyte pathobiology, and macrophage migration. Additionally, it has been investigated preclinically as a therapeutic candidate for several indications: by Amgen for diabetes and liver disease (Kupffer cell polarization), by the National Health Research Institute (NHRI) in Taiwan for SARS-CoV-2-mediated thromboinflammation, and by the University of Birmingham for peritonitis and tissue inflammation.
- Other names
- CLEC-2-FcCLEC2-FcCLEC 2-FcCLEC2.FcCLEC-2.FcCLEC 2.FcFc-CLEC2Fc-CLEC-2Fc-CLEC 2Fc-CLEC2(ECD)Recombinant Human CLEC-2/CLEC1B Fc Chimera ProteinrCLEC-2-FcrCLEC2-FcrCLEC 2-Fc
02
Targets
PDPN (Podoplanin)SARS-CoV-2 spike
Beyond the preview
Go deeper on Fc-CLEC-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fc-CLEC-2.